The 24-month results of the EVEREST II (Endovascular Valve Edge-to-Edge REpair Study), presented at the American College of Cardiology 2011 Scientific Sessions/i2 Summit and recently published (1) , investigating the safety and efficacy of the MitraClip (Abbott Vascular, Santa Clara, California) device, validated the interest in percutaneous approaches to the treatment of mitral regurgitation (MR) compared with the current gold standard, which is surgical mitral valve repair or replacement (2) . The MitraClip is a percutaneously inserted device that mimics the surgical edge-to-edge repair developed by Dr. Ottavio Alfieri in 1991, by attaching to the tips of the anterior and posterior mitral leaflets, securing them together to form a double-orifice mitral inlet, and thereby reducing the amount of regurgitation (3).
Trial Results and Implications
The EVEREST II randomized 279 patients with severe (3 to 4ϩ) MR to percutaneous mitral valve clip or open surgical valve repair or replacement. Patients were followed for 30 days and 1 year with primary endpoints of major adverse events and clinical success rate, respectively. Clinical success was defined as freedom from death, open mitral valve repair or replacement, and improvement of at least 2 grades of MR. At 30 days, there was a significant reduction in the composite endpoint of major adverse events (including death, myocardial infarction, stroke, reoperation, blood transfusion, and renal failure) at 9.6% in the percutaneous mitral clip group compared with 57% in the surgical group. At 1 year, clinical success was higher in the surgically treated group compared with the mitral clip arm. At 2 years, intention-to-treat analysis revealed that the primary composite endpoints were still significantly better in the surgery group compared with the mitral clip group.
The conclusion of the EVEREST II is that percutaneous mitral valve repair, although less effective at reducing MR, is not inferior to surgical repair or replacement, with a significantly reduced adverse event rate; however, several questions remain. First, an edge-to-edge repair would only be suitable for a select group of patients with central MR or flail leaflet and would not address the other leaflet morphologies of MR. Almost one-third of patients in the MitraClip group had functional MR with reportedly no difference in outcome (reduced left ventricular volume/dimension and improved symptoms) compared with the degenerative MR patients; however, the durability of this result beyond 2 years remains to be seen. Second, the improvement in symptoms and left ventricular size, although similar in both groups, may begin to diverge as patients are followed because a 3-fold greater percentage of device-treated patients had 2ϩ or greater MR severity compared with surgically treated patients. In addition, although most patients remain candidates for surgical repair after MitraClip therapy, there have also been reports of mitral clip patients with persistent severe MR who, due to significant mitral leaflet scarring, are unable to have surgical mitral valve repair and must undergo valve implantation. More than 15% of patients in the device arm subsequently underwent mitral valve surgery due to persistent severe MR. The inclusion of requiring blood transfusions, instead of the incidence of major bleeding, as an adverse event in the study has drawn criticism; however, it should be noted that adverse events continue to favor device-treated patients even if major bleeding is taken into account and that transfusion after cardiac surgery is associated with increased acute and long-term mortality (4-8).
Summary and Future Direction
The (9) . The AMADEUS (cArillon Mitral Annuloplasty Device European Union Study) (10) evaluated the use of the Carillon device (Cardiac Dimensions, Kirkland, Washington), which consists of an arched nitinol wire with looped anchors at each end that is delivered percutaneously via the coronary sinus and anchored in the great cardiac vein, restoring the natural shape of the mitral annulus by modifying the tension of the device. At 6 months, MR reduction and improvement in 6-min walk distance and quality of life were achieved with permanent implantation in 30 of 48 patients enrolled (11) .
Two indirect annuloplasty devices are no longer being studied, but some clinical results are reported. The EVOLUTION phase I study (Clinical Evaluation of the Edwards Lifesciences Percutaneous Mitral Annuloplasty System for the Treatment of Mitral Regurgitation) (12) used the MONARC coronary sinus device (Edwards Lifesciences, Irvine, California), which consists of 2 stent anchors with a connecting spring bridge and a biodegradable element within the bridge. At 12 months, MR reduction more than 1 grade was observed in 50% of implanted patients and in 85.7% of patients with baseline MR more than 3 grades (12) . The EVOLUTION phase II study of a second-generation coronary sinus ring for patients with at least 3ϩ MR has been concluded, but results have not yet been made available. The Percutaneous Mitral Annuloplasty (PTMA) device (Viacor Inc., Wilmington, Massachusetts) is a trilumen plastic cannula that is used to deliver nitinol rods into the coronary sinus to compress the septolateral dimension and allow improved leaflet coaptation. MR reduction was observed in 13 of 19 patients who received a diagnostic PTMA device (13) .
Two direct mitral annuloplasty approaches including the Mitralign system (Mitralign, Tewksbury, Massachusetts) and the Guided Delivery Systems device (Guided Delivery Systems, Santa Clara, California) have undergone first-inhuman feasibility studies, but larger clinical outcome trials are pending.
The MitraClip is the first step in catheter-based strategy for percutaneous treatment of MR. The initial study describing the surgical Alfieri technique for treatment of MR (14) demonstrated 22% greater freedom from reoperation when double-orifice repair was combined with an annuloplasty procedure. The effectiveness of percutaneous mitral valve repair may be improved when performed in conjunction with the use of other catheter-based annuloplasty devices that are currently in development. At this point, it is clear that the MitraClip procedure is safe, with clinical benefits in selected patients who are stable at least for 2 years. The regulatory steps involved in evaluation for FDA approval and the subsequent rate of incorporation into clinical practice will determine future developments of the MitraClip and other mitral valve devices.
